NCT06481332进行中（未招募）不适用
Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Event-free survival
研究概览
简要总结
Evaluation of Event free survival in patients with triple-negative thrombocytosis
详细描述
Patients with non-reactive thrombocytosis, explored at least by bone marrow biopsy and NGS panel will be included. Clinical and biological characteristics as well as evolution will be recorded retrospectively.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with non reactive thrombocytosis for at least 6 months
- •availability of bone marrow biopsy and NGS panel
排除标准
- •Unable to consent
结局指标
主要结局
Event-free survival
时间窗: 3 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with advanced Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 17.0Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864EUCTR2011-000114-19-DEGlaxoSmithKline Research and Development Ltd160
Unknown
2 期
To evaluate the long-term durability of clinicalbenefit as well as overall survival, the long-term safety and tolerability of eltrombopag in subjects with myelodysplastic syndromesand acute myeloid leukemia.CTRI/2012/08/002911GlaxoSmithKline Pharmaceuticals Ltd140
进行中（未招募）
1 期
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 14.0Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000114-19-GRGlaxoSmithKline Research and Development Ltd160
进行中（未招募）
1 期
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with advanced Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 14.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000114-19-IEGlaxoSmithKline Research and Development Ltd160
进行中（未招募）
不适用
Treatment of Low Platelet Counts Due to advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with EltrombopagThrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid LeukemiaMedDRA version: 14.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10060356Term: Acute myeloid leukaemia without mention of remissionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000114-19-NLGlaxoSmithKline Research and Development Ltd160